Keya Medical Secures Over RMB 300 Million in Series D Funding, Accelerating AI Medical Product Development and Commercial Expansion

Recently, Keya Medical (Beijing Keya Fangzhou Medical Technology Co., Ltd.), a leading enterprise in China’s AI medical device industry, announced that it had secured over RMB 300 million in Series D financing. This round was jointly invested by new and existing shareholders, including CICC Capital, Shanghai Artificial Intelligence Industry Fund, Gaozu Asset, and Yueyin Medical Fund. The proceeds will be used to support Keya Medical’s product development and business expansion in the field of AI healthcare.

This financing round marks the third round completed by Keya Medical within the six-month period of the second half of this year! Thus, in 2020 alone, Keya Medical progressed from Series B to Series D, securing multiple rounds of large-scale financing. In terms of both fundraising speed and scale, it has taken a leading position in China’s medical AI industry. This achievement is closely tied to Keya Medical’s rapid advancement of product commercialization and marketing layout, following its acquisition of China’s first NMPA Class III certificate for artificial intelligence, thanks to its outstanding and pioneering R&D perspective.

Medical AI is not an industry characterized by “quick investment and rapid returns.” It is widely acknowledged that commercializing medical AI products is challenging, requiring robust product capabilities, refined management, and a complete commercial ecosystem for successful implementation.

In response, Dr. Song Qi, CEO of Keya Medical, stated, “We believe that the primary challenges in the commercialization of AI-based medical devices lie in ‘standard acceptance and value recognition.’ It is precisely because Keya Medical has identified and initially addressed these two major challenges that we have attracted significant capital attention and achieved our current success.”

First, in terms of “standard recognition.” Throughout the entire process of product research and development and manufacturing, Keya Medical has maintained thoughtful deliberation in every decision regarding its products. This approach ensures a clear analysis of each stage of the product’s development and clarifies its future growth trajectory. Consequently, during the regulatory approval process for product registration, Keya Medical enabled the competent authorities to not only understand the technical capabilities of the product but also recognize its practical applicability and subsequent revenue potential. With guidance and support from the regulatory authorities, Keya Medical continuously improved its compliance framework, ultimately obtaining China’s first Class III medical device certificate for artificial intelligence. This achievement successfully realized the “standard recognition” of its products.

“Value recognition” is reflected in the clinical application value and market returns of AI medical technology products. Keya Medical has established “continuous refinement and deep cultivation of the clinical application value of its products” as the primary principle of its R&D, with the core philosophy of “basing on real clinical needs to enhance smart healthcare applications.” To uphold this principle and philosophy, Keya Medical has built a comprehensive AI medical product R&D pipeline spanning from needs analysis and data collection to algorithm design and verification/validation. This approach explains why, during the early stages of product development, when most domestic medical AI companies were crowding into pulmonary nodule and fundus screening, Keya Medical did not follow the trend. Instead, through in-depth observation grounded in clinical needs and practical applications, it chose to develop CT-FFR products—an area rarely explored by peers. By leveraging deep learning technologies to improve and optimize existing CT-FFR detection methods, Keya Medical provided clinicians with new diagnostic tools and developed “DeepVessel FFR,” the industry’s first certified product of its kind, which has gained recognition from both the clinical community and the market.

The “industry’s first certification” label has also pressed the “fast-forward button” on Keya Medical’s marketing pace. With the successful completion of multiple rounds of financing, Keya Medical has rapidly advanced its nationwide commercialization layout. The original team of 150 has nearly doubled in size, with 65% of the new hires joining the sales team. Its market scale has expanded significantly from nearly 120 partner hospitals and over 70 co-built centers at the beginning of the year to product implementation across more than 30 provinces in China. Notably, it has completed price applications for new medical service items in multiple provinces and municipalities, achieving partnerships with over 500 hospitals, establishing more than 300 AI diagnostic centers, and covering over 22 million patients. This rapid capture of the domestic market has further solidified Keya Medical’s position as a leader in China’s medical AI industry.

Today, Keya Medical has established an effective closed loop around its core strengths of “R&D (leading-edge technology development), manufacturing (compliant product production), and application (alignment with clinical practice).” Proactively, the company has built a next-generation AI medical device platform. Through collaborative development with healthcare institutions and life sciences research organizations, it has sequentially launched more than ten products across three major series: the Precision Diagnosis and Treatment Series for Vascular Diseases, the Precision Diagnosis and Treatment Series for Oncology, and the Intelligent Imaging Diagnosis and Treatment Series. By strategically positioning itself within a comprehensive health management service ecosystem, Keya Medical has achieved end-to-end coverage for single-disease management, encompassing early screening, diagnosis, and treatment.

When discussing the company’s plans for the coming year, Dr. Song Qi continues to uphold “pragmatism” as the guiding principle for Keya Medical’s development. “With multiple initiatives proceeding in parallel, we will remain deliberate and thoughtful in every decision we make. This approach ensures that we can clearly analyze the development stage of each product and define its future trajectory. For products that have already received regulatory approval, we will continue our efforts to include them in the price catalogs of medical institutions across more cities, while simultaneously expanding their technical applications to maintain their clinical utility and technological leadership. Furthermore, in the fields of cardiology, radiology, and surgical oncology, we aim to deliver even more breakthroughs in the new year.”

It is reported that multiple products across Keya Medical’s three major series have been refined to maturity, while the company’s product compliance initiatives are advancing rapidly and steadily. With prior experience securing CE, FDA, and NMPA certifications, Keya Medical is poised to obtain additional product approvals in the coming year, further accelerating its global market expansion. Leveraging its strong development potential and high growth trajectory, the company is expected to generate greater commercial value and is well-positioned to become an early entrant into the capital markets.